{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:04Z","timestamp":1791343444367,"version":"4.3.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T00:00:00Z","timestamp":1351641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>FMS\u2010like tyrosine kinase III (<jats:italic>FLT3<\/jats:italic>) mutations occur in one\u2010third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of <jats:italic>FLT3<\/jats:italic> in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with <jats:italic>FLT3<\/jats:italic> mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, <jats:italic>FLT3<\/jats:italic> mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. <jats:italic>FLT3<\/jats:italic> mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had <jats:italic>FLT3\u2010ITD<\/jats:italic> mutation and 3 had <jats:italic>FLT3\u2010<\/jats:italic>tyrosine kinase domain (<jats:italic>TKD<\/jats:italic>) mutation. MDS patients with <jats:italic>FLT3<\/jats:italic> mutations were younger (<jats:italic>P<\/jats:italic> = 0.02) and presented as RAEB (<jats:italic>P<\/jats:italic> = 0.03) more frequently. Median overall survival (OS) for <jats:italic>FLT3<\/jats:italic>\u2010mutated MDS patients was 19.0 months versus 16.4 months for <jats:italic>FLT3<\/jats:italic>\u2010nonmutated MDS patients (<jats:italic>P<\/jats:italic> = 0.08). <jats:italic>FLT3<\/jats:italic> mutations were identified in 13 (4.3%) CMML patients: 8 had <jats:italic>FLT3\u2010ITD<\/jats:italic> mutation and 5 had <jats:italic>FLT3\u2010TKD<\/jats:italic> mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without <jats:italic>FLT3<\/jats:italic> mutations. Median OS for <jats:italic>FLT3<\/jats:italic>\u2010mutated CMML patients was 10.8 months versus 21.3 months for <jats:italic>FLT3<\/jats:italic>\u2010nonmutated CMML patients (<jats:italic>P<\/jats:italic> = 0.12). <jats:italic>FLT3<\/jats:italic> occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome. Am. J. Hematol. 2013. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23345","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T13:23:31Z","timestamp":1349961811000},"page":"56-59","source":"Crossref","is-referenced-by-count":97,"title":["<i>FLT3<\/i> mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia"],"prefix":"10.1002","volume":"88","author":[{"given":"Naval","family":"Daver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Qin Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,31]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06566.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4430"},{"key":"e_1_2_5_4_2","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao M","year":"1996","journal-title":"Leuk: Off J Leuk Soc Am Leuk Res Fund UK"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.01.010"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4326"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196055"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1752"},{"key":"e_1_2_5_9_2","first-page":"7233","article-title":"Absence of the wild\u2010type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study","volume":"61","author":"Whitman SP","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-091215"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400770"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403274"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20440"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/JT5BE2L1FGG8P8Y6"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.013"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11636"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.59"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V114.22.826.826","article-title":"Prognostic impact of FLT3 mutation load in NPM1 mutated AML","volume":"114","author":"Schnittger S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.175"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400812"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01284.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10869"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.4.12612"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06171.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-001149"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V114.22.636.636","article-title":"AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first\u2010in\u2010human (FIH) phase 1 AML Study","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9678"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4888"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222034"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23345","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:43:08Z","timestamp":1700620988000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,31]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/ajh.23345"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23345","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,31]]}}}